More on MRK

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-100.0% Growth)
- Ratings (7.4 Score)
- Holders
- Dividends (2.9% Yield)
- Event Driven Deals
- FDA Archive

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (7/29/26 *Est.)
- M&A (6/30/19 *Est)
- M&A (6/30/21 *Est)
- M&A (3/31/23 *Est)
- M&A (9/30/23 *Est)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Merck (NY:MRK)
Delayed: 115.79 -0.28 (0.24%)
Prev. Close $116.07  
Open$115.15 
52 Wk High$65.46 
52 Wk Low$47.97 
Day High$116.36 
Day Low$113.82 
P/E 78.77  
EPS$1.47 
Volume12,809,060 

Friends, Peers and Foes (?): PFE, LLY, MKKGY, ABBV, AMGN (more...)

Mar 4, 2026 08:00 AM NeOnc Technologies sets phase 2 dose for brain cancer drug NEO212
Mar 4, 2026 08:00 AM NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m.
Mar 2, 2026 05:31 PM Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
Mar 2, 2026 06:26 AM Merck (MRK) PT Raised to $129 at Leerink Partners
Feb 28, 2026 10:05 AM KEYTRUDA Plus WELIREG Shows 28% Reduction in Cancer Recurrence Risk
Feb 28, 2026 10:05 AM KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlie
Feb 28, 2026 10:00 AM WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carc
Feb 27, 2026 10:15 AM KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients
Feb 27, 2026 10:04 AM Merck's KEYTRUDA plus Padcev reduces bladder cancer risk in trial
Feb 27, 2026 10:00 AM KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladd
View All Articles

Entities mentioned with MRK

View All Entities